Abstract 1579P
Background
The US Surveillance, Epidemiology, and End Result (SEER) data indicated an increasing incidence of early-onset GI tract cancers. According to published data, the treatment outcomes of young adults (YA) are comparable to the general population. We aimed to analyze the clinicopathological characteristics and overall survival (OS) of YA treated in a comprehensive cancer center.
Methods
Patients diagnosed with oesophagal (OC), oesophagogastric junction (OGJ), or gastric (GC) cancer between 2010 and 2022 were retrospectively identified from the Masaryk Memorial Cancer Institute database. Inclusion criteria were 1) age 18-50 years, 2) histology, and 3) treatment according to international recommendations.
Results
The consecutive patient cohort included 1725 patients, of which 162 met the inclusion criteria, representing approximately 10% of YA patients from the Czech Republic. In 63% of cases, the patients were men, significantly older than women (84% vs 65% in the age group 40-49 years, p=0.005). In women, tumors were more often located in the stomach (78% vs 53%, p=0.001) and primary metastatic (67% vs 50%, p=0.039). Six patients had localized disease (stage I), 36 (16 OC/OGJ, 20 GC) underwent radical resection, 31 (15 OC/OGJ, 16 GC) were unresectable, and 86 metastatic (25 OC/OGJ, 61 GC). With a median follow-up of 67 months, 131 (81%) deaths were recorded. Radically resected patients achieved a median OS of 54 mo with a 5-year OS of 42%, whereas the median OS for the unresectable and metastatic disease was 11 mo, and 8.6 mo, respectively.
Conclusions
In our YA cohort, men were older, while women were more likely to have metastatic gastric cancer. OS for the locally advanced disease was comparable to published studies observing the general population but noticeably shorter for metastatic disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22